Volume 49, Issue 10 , Pages 1001-1010, October 2010
National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007
Objective
To examine patterns and recent trends in multiclass psychotropic treatment among youth visits to office-based physicians in the United States.
Method
Annual data from the 1996-2007 National Ambulatory Medical Care Surveys were analyzed to examine patterns and trends in multiclass psychotropic treatment within a nationally representative sample of 3,466 child and adolescent visits to office-based physicians in which a psychotropic medication was prescribed.
Results
There was an increase in the percentage of child visits in which psychotropic medications were prescribed that included at least two psychotropic classes. Across the 12 year period, multiclass psychotropic treatment rose from 14.3% of child psychotropic visits (1996-1999) to 20.2% (2004-2007) (adjusted odds ratio [AOR] = 1.89, 95% confidence interval [CI] = 1.22-2.94, p < .01). Among medical visits in which a current mental disorder was diagnosed, the percentage with multiclass psychotropic treatment increased from 22.2% (1996-1999) to 32.2% (2004-2007) (AOR = 2.23, 95% CI = 1.42-3.52, p < .001). Over time, there were significant increases in multiclass psychotropic visits in which ADHD medications, antidepressants, or antipsychotics were prescribed, and a decrease in those visits in which mood stabilizers were prescribed. There were also specific increases in co-prescription of ADHD medications and antipsychotic medications (AOR = 6.22, 95% CI = 2.82-13.70, p < .001) and co-prescription of antidepressant and antipsychotic medications (AOR = 5.77, 95% CI = 2.88-11.60, p < .001).
Conclusions
Although little is known about the safety and efficacy of regimens that involve concomitant use of two or more psychotropic agents for children and adolescents, multiclass psychotropic pharmacy is becoming increasingly common in outpatient practice.
Key Words: national trends, pediatric psychopharmacology, polypharmacy
To access this article, please choose from the options below
This work was supported by AHRQ U18 HS016097 and NIH T32 MH016434.
The authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Disclosure: Dr. Olfson, in the past 5 years, has received investigator initiated grants from AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Co. He has served on the speakers' bureau for Janssen Pharmaceutica, and as a consultant to Pfizer, AstraZeneca, Eli Lilly and Co., and Bristol-Myers Squibb. Dr. Mojtabai has received research funding and consulting fees from Bristol-Myers Squibb. Dr. Comer reports no biomedical financial interests or potential conflicts of interest.
PII: S0890-8567(10)00561-7
doi:10.1016/j.jaac.2010.07.007
© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 49, Issue 10 , Pages 1001-1010, October 2010
